Baxter International Inc
BAX: XNYS (USA)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| <cD | LOCK|BYb& | LOCK|@@ |
Baxter Earnings: Novum Pump and Other Challenges Cut Into 2025 and Intermediate-Term Outlook
In the second quarter, Baxter turned in 1% operational sales growth and 28% adjusted EPS growth. Also, management reduced its guidance for 2025, including operational sales growth of 3% to 4% (down from 4% to 5% previously) and adjusted EPS of $2.42 to $2.52 (down from $2.47 to $2.55).
